Carboplatin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Carboplatin: From Ovarian Cancer to Female Breast Carcinoma
One-Sentence Summary
Carboplatin is a second-generation platinum-based chemotherapy agent originally established for ovarian cancer treatment, with additional clinical use across lung, bladder, and head-and-neck cancers. The TxGNN model predicts it may be effective for Female Breast Carcinoma, with the evidence base already at L1 — supported by multiple completed Phase III RCTs and 20 publications — including the landmark GeparSixto trial, BCIRG-006, and the ongoing KEYNOTE-868 programme. The prediction accurately reflects an indication where carboplatin has transitioned well beyond hypothesis into established clinical practice for specific subtypes, making expedited adoption appropriate with appropriate safeguards.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ovarian cancer (established global clinical use; no Saudi Arabia registration on record) |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L1 |
| Saudi Arabia Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Carboplatin is a platinum coordination compound that forms interstrand DNA cross-links, triggering irreparable double-strand breaks and subsequent apoptosis. Detailed pharmacological data were not captured in the current Evidence Pack; however, carboplatin's mechanism is well-characterised from decades of clinical use. The key mechanistic insight is that tumour cells harbouring homologous recombination deficiency (HRD) — most commonly driven by BRCA1/2 mutations or epigenetic silencing of DNA repair genes — are unable to resolve platinum-induced DNA damage, rendering them exquisitely sensitive to carboplatin. This biological vulnerability is far more prevalent in breast cancer than in many other solid tumours.
Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are the two subtypes where carboplatin's role is best established. TNBC lacks targetable hormone and HER2 receptors, leaving chemotherapy as the primary systemic treatment; the BRCA1/2 germline mutation rate in TNBC approaches 10–20%, and HRD rates (including non-BRCA causes) are higher still. In HER2-positive disease, the TCbHP regimen — docetaxel, carboplatin, trastuzumab, pertuzumab — exploits synergy between platinum-induced DNA damage and HER2 pathway blockade, achieving high pathologic complete response (pCR) rates without anthracycline-related cardiotoxicity. The functional connection between ovarian cancer (where HRD is endemic) and breast cancer is mechanistically direct: both tumour types share the BRCA1/2 mutation landscape, and carboplatin's efficacy in one predicts activity in the other.
The TxGNN model's 99.86% score for this repurposing direction is therefore not a speculative extrapolation — it reflects a graph-neural-network recognising an already well-validated biological connection. Clinical data have confirmed what the model predicts, making this among the strongest drug-indication pairings in the TxGNN output for carboplatin.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00021255 | Phase 3 | Completed | 3,222 | BCIRG-006: TCH (docetaxel/carboplatin/trastuzumab) vs AC-TH vs AC-T in HER2+ operable breast cancer. TCH demonstrated non-inferior disease-free survival with significantly lower cardiac toxicity than anthracycline-containing arms; foundational evidence establishing carboplatin as a standard adjuvant component in HER2+ disease |
| NCT02003209 | Phase 3 | Completed | 315 | Randomised Phase III: TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab) ± oestrogen deprivation as neoadjuvant therapy for HR+/HER2+ locally advanced breast cancer; evaluates pCR as primary endpoint and confirmed carboplatin as core of the dual-HER2-blockade neoadjuvant backbone |
| NCT01881230 | Phase 2/3 | Completed | 191 | Nab-paclitaxel + gemcitabine or carboplatin vs gemcitabine/carboplatin doublet as first-line treatment in triple-negative metastatic breast cancer; directly compares carboplatin-containing regimens in the TNBC first-line setting |
| NCT02413320 | Phase 2 | Completed | 101 | Randomised neoadjuvant: carboplatin/docetaxel vs carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide in stage I–III TNBC; evaluates whether the pairing drug affects carboplatin's contribution to pCR |
| NCT02978495 | Phase 2 | Completed | 154 | NACATRINE trial: neoadjuvant carboplatin in TNBC, with particular focus on BRCA1/2 mutation carriers; conducted in Brazil, demonstrating real-world feasibility across diverse populations |
| NCT03639948 | Phase 2 | Active, not recruiting | 120 | Pembrolizumab + carboplatin/docetaxel neoadjuvant regimen in stage I–III TNBC; assesses whether PD-1 blockade synergises with carboplatin-induced immunogenic cell death to improve pCR |
| NCT06291064 | Phase 2 | Recruiting | 85 | TARMAC trial: epirubicin/cyclophosphamide followed by docetaxel/carboplatin in Nigerian women with TNBC; uses blood biomarkers to identify chemoresistance, extending carboplatin evidence to under-represented populations |
| NCT04083963 | Phase 2 | Active, not recruiting | 13 | Weekly carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide in operable TNBC; evaluates simplified weekly platinum scheduling for improved tolerability |
| NCT07528898 | Phase 2 | Not yet recruiting | 100 | Response-guided neoadjuvant SHR-A1811 (anti-HER2 ADC) + pertuzumab vs standard carboplatin-based therapy in HER2+ early/locally advanced breast cancer; carboplatin arm serves as the current standard-of-care comparator |
| NCT06234137 | N/A | Recruiting | 154 | Docetaxel/carboplatin + inetetamab + pyrotinib (TCbIP) as neoadjuvant therapy for locally advanced HER2+ breast cancer; evaluates total pathologic complete response (tpCR) and long-term event-free survival |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24794243 | 2014 | RCT (Phase II/III) | Lancet Oncology | GeparSixto: Adding carboplatin to neoadjuvant chemotherapy significantly improved pCR in TNBC (53.2% vs 36.9%; p=0.005) and showed a trend in HER2+ disease; established carboplatin as a neoadjuvant standard in TNBC |
| 33208340 | 2021 | Phase II RCT | Clinical Cancer Research | NeoSTOP (multisite): Anthracycline-free carboplatin/taxane regimen achieved comparable pCR rates to anthracycline-containing carboplatin regimens in stage I–III TNBC, supporting carboplatin as sufficient backbone without anthracycline toxicity |
| 39671272 | 2025 | RCT | JAMA | CamRelief: Camrelizumab (anti-PD-1) combined with carboplatin-containing neoadjuvant chemotherapy significantly improved pCR vs chemotherapy alone in early/locally advanced TNBC; reflects carboplatin's continued role as immunotherapy backbone |
| 40593759 | 2025 | RCT (Phase 2b) | Nature Communications | MUKDEN 06: ARX788 + pyrotinib vs standard TCbHP neoadjuvant in HER2+ breast cancer; TCHP arm (carboplatin-containing) used as the active comparator, confirming its status as the current gold-standard comparator in HER2+ neoadjuvant trials |
| 38309017 | 2024 | Phase III RCT | European Journal of Cancer | BROCADE3 final overall survival data: Veliparib + carboplatin/paclitaxel vs placebo + carboplatin/paclitaxel in BRCA1/2-mutated HER2-negative advanced breast cancer; improved PFS demonstrated; confirms carboplatin as preferred backbone in BRCA-mutated advanced disease |
| 35462344 | 2022 | Individual-patient meta-analysis | Breast | Pooled individual-participant data meta-analysis confirms that adding carboplatin to neoadjuvant/adjuvant chemotherapy in TNBC improves both pCR rate and overall survival — resolving prior uncertainty on survival benefit |
| 40329228 | 2025 | Real-world cohort | BMC Cancer | Multicenter real-world analysis: carboplatin in neoadjuvant chemotherapy improved pCR and survival in TNBC regardless of HER2-low or HER2-zero status, broadening the applicable population |
| 40779028 | 2025 | Phase I/II | Breast Cancer Research and Treatment | Carboplatin + gemcitabine + mifepristone in advanced breast and ovarian cancer: mifepristone (glucocorticoid receptor antagonist) enhances carboplatin-induced apoptosis by blocking GR-mediated chemoresistance — mechanism-expanding combination |
| 40468999 | 2025 | Phase II | Acta Oncologica | TCHL 5-year follow-up: TCH (docetaxel/carboplatin/trastuzumab) ± lapatinib as neoadjuvant for HER2+ breast cancer; long-term efficacy and serum biomarker predictors reported, supporting sustained carboplatin activity |
| 33256829 | 2020 | Phase II | Breast Cancer Research | Carboplatin + bevacizumab in breast cancer brain metastases: demonstrated meaningful intracranial responses in a population with very limited systemic options, expanding carboplatin's role into CNS-involved disease |
Saudi Arabia Market Information
Carboplatin does not currently hold any drug authorizations in Saudi Arabia (0 registered products, market status: not marketed). Clinicians wishing to use carboplatin in Saudi Arabia would need to source it through special import authorisation or named-patient/compassionate use programmes under SFDA regulations.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic — Platinum-based alkylating agent (second-generation platinum compound) |
| Myelosuppression Risk | High — Thrombocytopenia is the dose-limiting toxicity; neutropenia and anaemia are also common, especially in combination with taxanes. In the TCHP regimen, grade 3/4 anaemia occurred in up to 40% of patients, with dose reduction of carboplatin associated with reduced transfusion requirements (PMID 35837812). High-dose carboplatin regimens (AUC ≥6) carry greater risk. |
| Emetogenicity Classification | Moderate to high — Carboplatin at AUC ≥4 is classified as highly emetogenic per MASCC/ESMO guidelines; appropriate prophylactic antiemetic regimens (NK1 antagonist + 5-HT3 antagonist + dexamethasone) are required |
| Monitoring Items | Complete blood count with differential (before each cycle, and mid-cycle if high-dose); serum creatinine and calculated GFR (carboplatin dosing via Calvert formula requires accurate GFR); electrolytes (Mg²⁺, K⁺, Ca²⁺); audiological assessment for high-dose regimens (ototoxicity reported in salvage HD-carboplatin contexts); baseline and ongoing peripheral neuropathy assessment when combined with taxanes |
| Handling Protection | Must follow cytotoxic drug handling regulations; prepare under vertical laminar airflow biological safety cabinet (Class II or III); wear double chemotherapy gloves, impermeable gown, and eye/face protection; use closed-system drug transfer devices (CSTDs) to minimise aerosolisation; all waste classified as cytotoxic/hazardous waste |
Safety Considerations
Please refer to the package insert for safety information.
Note: SFDA package insert data and key warnings/contraindications were not available in the current Evidence Pack (Data Gap DG001). A complete safety review — including renal function thresholds for dose reduction, pregnancy/lactation contraindications, and specific drug interaction warnings — must be conducted against the product package insert prior to clinical use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase III randomised trials (BCIRG-006: n=3,222; TCHP neoadjuvant: n=315; BROCADE3) and the pivotal GeparSixto Phase II/III trial collectively establish carboplatin as an evidence-based treatment option for female breast carcinoma — specifically in TNBC and HER2-positive subtypes — meeting the L1 evidence threshold for clinical adoption. The TxGNN model's 99.86% prediction score accurately reflects the strength of this pre-existing clinical evidence base.
To proceed, the following is needed:
- Import authorisation: Carboplatin is not currently registered in Saudi Arabia; procurement via SFDA special import or named-patient pathway must be arranged before clinical use
- Safety data gap resolution: Obtain and review the SFDA/product-specific package insert (Data Gap DG001) to confirm key warnings, contraindications, and dose adjustment criteria for renal impairment — mandatory before initiating treatment
- MOA documentation: Retrieve complete pharmacological data from DrugBank (Data Gap DG002) to support the institutional repurposing dossier
- Patient selection criteria: Define biomarker-driven eligibility — BRCA1/2 germline testing and HRD status assessment are strongly recommended, as carboplatin benefit is most pronounced in HRD-positive TNBC; subtype-specific protocols should be differentiated (TNBC vs HER2-positive)
- Haematological monitoring protocol: Establish pre-treatment baseline CBC, renal function (GFR for Calvert dosing), and electrolytes, with a cycle-by-cycle monitoring schedule and pre-defined dose-reduction thresholds for thrombocytopenia and anaemia
- Audiological monitoring plan: Required if high-dose carboplatin regimens (AUC >6) or salvage regimens with cumulative platinum exposure are considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.